[go: up one dir, main page]

BRPI0808052A2 - Método para tratar ou prevenir inflamação sistêmica. - Google Patents

Método para tratar ou prevenir inflamação sistêmica.

Info

Publication number
BRPI0808052A2
BRPI0808052A2 BRPI0808052-6A2A BRPI0808052A BRPI0808052A2 BR PI0808052 A2 BRPI0808052 A2 BR PI0808052A2 BR PI0808052 A BRPI0808052 A BR PI0808052A BR PI0808052 A2 BRPI0808052 A2 BR PI0808052A2
Authority
BR
Brazil
Prior art keywords
treat
systemic inflammation
prevent systemic
infant
prevent
Prior art date
Application number
BRPI0808052-6A2A
Other languages
English (en)
Inventor
Robert Mcmahon
William Michael Russell
Udo Herz
Josef Neu
Original Assignee
Mead Johnson Nutrition Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39469924&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BRPI0808052(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mead Johnson Nutrition Co filed Critical Mead Johnson Nutrition Co
Publication of BRPI0808052A2 publication Critical patent/BRPI0808052A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/745—Bifidobacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BRPI0808052-6A2A 2007-02-28 2008-02-22 Método para tratar ou prevenir inflamação sistêmica. BRPI0808052A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US90412207P 2007-02-28 2007-02-28
PCT/US2008/054710 WO2008106372A1 (en) 2007-02-28 2008-02-22 Method for treating or preventing systemic inflammation

Publications (1)

Publication Number Publication Date
BRPI0808052A2 true BRPI0808052A2 (pt) 2014-06-24

Family

ID=39469924

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0808145-0A BRPI0808145A2 (pt) 2007-02-28 2008-02-22 Produto contendo probiótico inativado para crianças ou lactentes.
BRPI0808052-6A2A BRPI0808052A2 (pt) 2007-02-28 2008-02-22 Método para tratar ou prevenir inflamação sistêmica.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0808145-0A BRPI0808145A2 (pt) 2007-02-28 2008-02-22 Produto contendo probiótico inativado para crianças ou lactentes.

Country Status (13)

Country Link
US (2) US9408819B2 (pt)
EP (2) EP2114423B2 (pt)
CN (3) CN101636172A (pt)
AT (1) ATE544457T1 (pt)
BR (2) BRPI0808145A2 (pt)
CA (2) CA2679374C (pt)
ES (2) ES2381232T3 (pt)
MX (2) MX2009008875A (pt)
MY (2) MY151892A (pt)
PL (2) PL2124977T3 (pt)
RU (2) RU2468808C2 (pt)
TW (2) TWI418355B (pt)
WO (2) WO2008106372A1 (pt)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7767203B2 (en) 1998-08-07 2010-08-03 Ganeden Biotech, Inc. Methods for the dietary management of irritable bowel syndrome and carbohydrate malabsorption
ES2381232T3 (es) * 2007-02-28 2012-05-24 Mead Johnson Nutrition Company Procedimiento para el tratamiento o la prevención de la inflamación sistémica
US9113641B2 (en) * 2007-12-06 2015-08-25 Arla Foods Amba Probiotic bacteria and regulation of fat storage
US9034314B2 (en) * 2008-11-03 2015-05-19 Nestec S.A. Nutritional composition comprising probiotics and improving sleep patterns
AU2010242955B2 (en) * 2009-04-29 2016-02-04 Ganeden Biotech, Inc. Inactivated bacterial cell formulation
EP2251020A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Short-time high temperature treatment generates microbial preparations with anti-inflammatory profiles
RU2556124C2 (ru) * 2009-05-11 2015-07-10 Нестек С.А. Lactobacillus johnsonii La1 NСС533 (CNCM 1-1225) И ИММУННЫЕ НАРУШЕНИЯ
EP2251022A1 (en) * 2009-05-11 2010-11-17 Nestec S.A. Non-replicating micro-organisms and their immune boosting effect
CA2786710C (en) * 2010-01-19 2018-10-09 Abbott Laboratories Nutritional formulas containing synbiotics
US9301982B2 (en) 2010-04-14 2016-04-05 Ganeden Biotech, Inc. Probiotic confection and lipid compositions
WO2012062900A2 (en) * 2010-11-11 2012-05-18 Nestec S.A. Frozen confections containing probiotic micro-organisms
EP2452576A1 (en) * 2010-11-11 2012-05-16 Nestec S.A. Extruded non-replicating probiotic micro-organisms and their health benefits
EP2455094A1 (en) 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect children against gastrointestinal infections
EP2455092A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic micro-organisms protect against upper respiratory tract infections
EP2455093A1 (en) * 2010-11-11 2012-05-23 Nestec S.A. Non-replicating probiotic bacteria and prevention or treatment of infections in children
WO2012135499A1 (en) 2011-03-31 2012-10-04 Ganeden Biotech, Inc. Probiotic sports nutrition compositions
GB201112091D0 (en) 2011-07-14 2011-08-31 Gt Biolog Ltd Bacterial strains isolated from pigs
GB201117313D0 (en) 2011-10-07 2011-11-16 Gt Biolog Ltd Bacterium for use in medicine
KR101166798B1 (ko) 2011-12-19 2012-07-26 김대현 락토바실러스 애시도필러스 엘비의 사균을 포함하는 알레르기 질환의 치료 또는 예방용 의약 조성물
US9545415B2 (en) * 2012-01-06 2017-01-17 Skyview Enterprise Ltd. Anti-inflammatory compounds in combination with hydrogen for the treatment of inflammation
US20130251829A1 (en) * 2012-03-23 2013-09-26 Mead Johnson Nutrition Company Probiotic derived non-viable material for infection prevention and treatment
GB201306536D0 (en) 2013-04-10 2013-05-22 Gt Biolog Ltd Polypeptide and immune modulation
US10265351B2 (en) * 2013-08-09 2019-04-23 Ab-Biotics, S.A. Probiotic for infantile colic
MX2016006503A (es) * 2013-11-25 2016-08-05 Nestec Sa Formulacion de bifidobacterium lactis ncc 2818 tratada con calor que reduce las manifestaciones alergicas.
CN118020922A (zh) * 2013-11-29 2024-05-14 雀巢产品有限公司 按年龄定制的具有不同蛋白质含量的营养组合物
HUE035569T2 (en) 2014-12-23 2018-05-28 4D Pharma Res Ltd Bacteroides thetaiotaomicron strain and its use in reducing inflammation
KR20170091157A (ko) 2014-12-23 2017-08-08 4디 파마 리서치 리미티드 피린 폴리펩티드 및 면역 조정
ES2753779T3 (es) 2015-06-15 2020-04-14 4D Pharma Res Ltd Blautia stercosis y wexlerae para la utilización en el tratamiento de enfermedades inflamatorias y autoinmunes
LT3360559T (lt) 2015-06-15 2019-12-27 4D Pharma Research Limited Kompozicijos, apimančios bakterijų kamienus
MA41010B1 (fr) 2015-06-15 2020-01-31 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
HUE045413T2 (hu) 2015-06-15 2019-12-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
MA41060B1 (fr) 2015-06-15 2019-11-29 4D Pharma Res Ltd Compositions comprenant des souches bactériennes
CN108513545B (zh) 2015-11-20 2020-11-03 4D制药研究有限公司 包含细菌菌株的组合物
GB201520497D0 (en) 2015-11-20 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520631D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
GB201520638D0 (en) 2015-11-23 2016-01-06 4D Pharma Res Ltd Compositions comprising bacterial strains
SG11201807195VA (en) 2016-03-04 2018-09-27 4D Pharma Plc Compositions comprising bacterial blautia strains for treating visceral hypersensitivity
GB201612191D0 (en) 2016-07-13 2016-08-24 4D Pharma Plc Compositions comprising bacterial strains
TW201821093A (zh) 2016-07-13 2018-06-16 英商４Ｄ製藥有限公司 包含細菌菌株之組合物
ES2657665B1 (es) * 2016-09-05 2018-12-17 Pedro Jose DE LA FUENTE BLASCO Productos para la salud con probióticos inactivados y uso de dichos productos
GB201621123D0 (en) 2016-12-12 2017-01-25 4D Pharma Plc Compositions comprising bacterial strains
CN107115362A (zh) * 2017-04-28 2017-09-01 青岛东海药业有限公司 凝结芽孢杆菌在制备预防或治疗支气管哮喘制剂中的应用
HUE054164T2 (hu) 2017-05-22 2021-08-30 4D Pharma Res Ltd Baktériumtörzseket tartalmazó készítmények
JP6978514B2 (ja) 2017-05-24 2021-12-08 フォーディー ファーマ リサーチ リミテッド4D Pharma Research Limited 細菌株を含む組成物
SMT202000695T1 (it) 2017-06-14 2021-01-05 4D Pharma Res Limited Composizioni comprendenti ceppi batterici
ES2855701T3 (es) 2017-06-14 2021-09-24 4D Pharma Res Ltd Composiciones que comprenden cepas bacterianas
JP2020523326A (ja) 2017-06-14 2020-08-06 フォーディー ファーマ リサーチ リミテッド４Ｄ Ｐｈａｒｍａ Ｒｅｓｅａｒｃｈ Ｌｉｍｉｔｅｄ 細菌株を含む組成物
CN108041607A (zh) * 2017-12-26 2018-05-18 广州普正生物科技有限公司 一种护齿益生菌咀嚼软胶囊
RU2770463C1 (ru) * 2020-10-14 2022-04-18 федеральное государственное бюджетное образовательное учреждение высшего образования "Алтайский государственный технический университет им. И.И. Ползунова" (АлтГТУ) Способ производства мягкого сыра
TWI802009B (zh) * 2021-09-16 2023-05-11 創百股份有限公司 使用熱致死的乳酸菌菌株來治療和/或預防微粒物質-誘發的肺損傷
WO2024236053A1 (en) 2023-05-15 2024-11-21 Bactopharma Gmbh Treatment of cancer therapy-induced oral mucositis

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5804179A (en) * 1985-12-31 1998-09-08 Research Corporation Technologies, Inc. Lactobacillus compositions and methods for treating urinary tract infections
RU2031586C1 (ru) * 1993-02-05 1995-03-27 Тамара Георгиевна Извекова Биологически активный кисломолочный продукт "ацидолакт-наринэ" и способ его получения
US6156320A (en) * 1993-02-05 2000-12-05 Harry Parsekian Fermented milk nutraceuticals
US6180100B1 (en) * 1994-09-30 2001-01-30 Urex Biotech., Inc. Lactobacillus compositions and methods for treating urinary tract infections
FI104465B (fi) * 1995-06-14 2000-02-15 Valio Oy Proteiinihydrolysaatteja allergioiden hoitamiseksi tai estämiseksi, niiden valmistus ja käyttö
ATE253640T1 (de) * 1998-06-17 2003-11-15 Nestle Sa Mobile genetische elemente als werkzeuge zur genetischen modifikation von l. delbrueckii oder l. helveticus
US6399055B1 (en) * 1998-10-27 2002-06-04 Compagnie Gervais Danone Method and composition for treatment of infant diarrhea
DE69924141D1 (de) * 1998-12-11 2005-04-14 Urex Biotech Inc Orale verabreichung von laktobacillus zur behandlung und prävention von urogenitalen infektionen
ID29150A (id) * 1999-01-15 2001-08-02 Entpr Ireland Cs Penggunaan lactobacillus salivarius
AU2001233529A1 (en) 2000-02-10 2001-08-20 Andrew W. Bruce Probiotic therapy for newborns
JP5186077B2 (ja) * 2000-12-18 2013-04-17 プロバイオヘルス・エルエルシー ラクトバシラス−カゼイｋｅ０１株から得られたプロバイオティック化合物
KR100419132B1 (ko) * 2000-12-29 2004-02-18 조성근 위·장 점막 부착성과 증식성, 내산성, 내담즙성 및헬리코박터 파일로리, 대장균 0157:ｈ7에 대한 항균성이우수한 락토바실러스 파라카제이 서브스패시즈 파라카제이ｃｓｋ 01
FI109602B (fi) * 2001-01-25 2002-09-13 Valio Oy Probioottiyhdistelmä
WO2002062360A1 (en) * 2001-02-06 2002-08-15 Societe Des Produits Nestle S.A. Endotoxin binding by lactic acid bacteria and bifidobacteria
PE20030284A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de bifidobacterium
PE20030283A1 (es) * 2001-07-26 2003-05-01 Alimentary Health Ltd Cepas de lactobacillus casei
PE20030274A1 (es) * 2001-07-26 2003-05-08 Alimentary Health Ltd Cepas de lactobacillus salivarius
EP1364586A1 (en) 2002-05-24 2003-11-26 Nestec S.A. Probiotics and oral tolerance
US20050100531A1 (en) * 2002-06-13 2005-05-12 John Bienenstock Probiotic therapies
ES2311729T5 (es) * 2002-06-28 2013-02-14 Biosearch S.A. Cepas probióticas, un procedimiento para la selección de ellas, composiciones de las mismas y su uso
US20040208863A1 (en) * 2003-01-30 2004-10-21 James Versalovic Anti-inflammatory activity from lactic acid bacteria
WO2004069156A2 (en) * 2003-01-30 2004-08-19 The Regents Of The University Of California Inactivated probiotic bacteria and methods of use thereof
EP1608383A1 (en) * 2003-03-31 2005-12-28 Alimentary Health Limited A formulation comprising a bacterial strain
WO2004112508A1 (en) * 2003-06-23 2004-12-29 Nestec S.A. Infant or follow-on formula
US7125963B2 (en) * 2004-03-03 2006-10-24 En N Tech Inc Treatments for contaminant reduction in lactoferrin preparations and lactoferrin containing compositions
WO2005087929A1 (en) * 2004-03-15 2005-09-22 Tissugen Pty Ltd Infectious aetiology of prostatic disease and methods to identify causative agents
CN101155616A (zh) * 2005-04-08 2008-04-02 宝洁公司 用于人类美容有益效果的口服益生菌双歧杆菌的使用方法
CA2604338A1 (en) 2005-04-13 2006-10-19 Nestec S.A. Infant formula with probiotics
US20060233762A1 (en) 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
US20060233752A1 (en) * 2005-04-15 2006-10-19 Mcmahon Robert J Method for treating or preventing systemic inflammation in formula-fed infants
WO2006124630A2 (en) * 2005-05-13 2006-11-23 New England Medical Center Hospitals, Inc. Compositions and methods for enhancing the efficacy of vaccines
ES2381232T3 (es) * 2007-02-28 2012-05-24 Mead Johnson Nutrition Company Procedimiento para el tratamiento o la prevención de la inflamación sistémica

Also Published As

Publication number Publication date
MY145769A (en) 2012-04-13
US9408819B2 (en) 2016-08-09
TWI494114B (zh) 2015-08-01
WO2008106373A1 (en) 2008-09-04
ES2381232T3 (es) 2012-05-24
CA2679374C (en) 2016-05-31
CN101678053B (zh) 2015-12-16
CN101636172A (zh) 2010-01-27
TW200900075A (en) 2009-01-01
CN105796607A (zh) 2016-07-27
BRPI0808145A2 (pt) 2021-03-23
RU2468808C2 (ru) 2012-12-10
CN101678053A (zh) 2010-03-24
CA2676956C (en) 2017-06-13
HK1136969A1 (en) 2010-07-16
WO2008106372A1 (en) 2008-09-04
EP2114423B1 (en) 2012-06-06
CA2679374A1 (en) 2008-09-04
PL2124977T3 (pl) 2012-07-31
US9408818B2 (en) 2016-08-09
CA2676956A1 (en) 2008-09-04
EP2114423A1 (en) 2009-11-11
US20080206213A1 (en) 2008-08-28
TWI418355B (zh) 2013-12-11
RU2009135871A (ru) 2011-04-10
MY151892A (en) 2014-07-14
ES2388198T3 (es) 2012-10-10
HK1141729A1 (zh) 2010-11-19
MX2009008875A (es) 2009-08-28
US20080206212A1 (en) 2008-08-28
EP2114423B2 (en) 2020-01-01
EP2124977B1 (en) 2012-02-08
MX2009009119A (es) 2009-09-04
RU2468807C2 (ru) 2012-12-10
RU2009135873A (ru) 2011-04-10
EP2124977A1 (en) 2009-12-02
TW200906426A (en) 2009-02-16
EP2124977B9 (en) 2012-05-02
PL2114423T3 (pl) 2012-10-31
ATE544457T1 (de) 2012-02-15
ES2388198T5 (es) 2020-07-14

Similar Documents

Publication Publication Date Title
BRPI0808052A2 (pt) Método para tratar ou prevenir inflamação sistêmica.
PH12014501749A1 (en) A nutritional composition comprising probiotics and improving sleep patterns
TW200507766A (en) Nutritional composition
MX2009009931A (es) Probioticos para reducir el desarrollo de alergia en lactantes nacidos por cesarea.
MX339112B (es) Formula alimenticia para bebes y niños pequeños que comprenden probioticos para bebes y niños pequeños.
TW200612971A (en) Method for preventing or treating respiratory infections and acute otitis media in infants
BR112013016903A2 (pt) oligossacarídeos de leite humano para modular inflamação
UA100985C2 (ru) Композиция для питания с нежизнеспособной бифидобактерией и неусваиваемым олигосахаридом
NZ613165A (en) Nutritional formulations including human milk oligosaccharides and long chain polyunsaturated fatty acids and uses thereof
BR112012003633A2 (pt) "composição nutricional que compreende cepas de bifidobacterium longum e reduz os sintomas de alergia alimentar, especialmente em bebês e crianças."
UA96984C2 (en) Reduction of risk diarrhoea
AR098598A1 (es) Composición nutricional con probióticos estables
BR112014001472A2 (pt) galactooligossacarídeos para prevenir lesões e / ou promover a cicatrização do trato gastrointestinal
MX338174B (es) Metodos para reducir la incidencia de la tension oxidativa al usar los oligosacaridos de leche humana, la vitamina c y los agentes antiinflamatorios.
MX2010008544A (es) Sistemas para y metodos de uso de nutricion terapeutica para el manejo de condiciones de salud asociadas con la edad y especificas de los adultos mayores.
CL2013001230A1 (es) Composicion a base de cereales en polvo que comprenden microorganismos probioticos no replicantes; y su uso para prevenir o tratar desordenes inflamatorios o trastornos con una defensa inmune comprometida en lactantes o niños pequeños.
BRPI0518855A2 (pt) medicamento para aplicaÇço higiÊnica no ouvido
PT1782818E (pt) Composição farmacêutica que compreende bacillus coagulans e simeticone para o tratamento de patologias gastrointestinais
Chantalakhana Contribution of water buffaloes in rural development
ES1059627Y (es) Maniqui bebe para la enseñanza y practica del masaje infantil.
RU2006122217A (ru) Способ предупреждения острых респираторных вирусных инфекций у детей дошкольного возраста
UA52520U (ru) Способ лечения нарушений функционального состояния кишечника у новорожденных и детей младенческого возраста
UA111872U (uk) Спосіб лікування еруптивного гінгівіту у дітей
TH126344A (th) องค์ประกอบทางโภชนาการซึ่งประกอบรวมด้วยโปรไบโอติก และปรับปรุงรูปแบบการนอนหลับ
Бєлєнька Education Line" Child in the natural environment"

Legal Events

Date Code Title Description
B25A Requested transfer of rights approved

Owner name: MJN U.S. HOLDINGS LLC (US)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]
B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2450 DE 19-12-2017 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.